Physician profile
Larry R Brazley
NPI 1093723793
$3,250.05
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,467 · 2020: $1,071 · 2021: $712.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $554.48 | 2019-2021 | |
| Amgen INC. | $547.90 | 2019-2021 | |
| Horizon Therapeutics Plc | $333.51 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $318.57 | 2020-2021 | |
| Pfizer INC. | $249.78 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $236.10 | 2019-2021 | |
| Lilly USA, LLC | $175.94 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $135.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.22 | 2019-2021 | |
| Ucb, INC. | $123.41 | 2019-2021 | |
| Janssen Biotech, INC. | $98.31 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $87.78 | 2021 | |
| Glaxosmithkline, LLC. | $83.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $76.14 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $28.51 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $26.44 | 2019 | |
| Medexus Pharma, INC. | $22.44 | 2019 | |
| Celgene Corporation | $13.72 | 2019 | |
| Genentech USA, INC. | $11.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Brazley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.